A new clinical study published in the International Journal of Gynecological Cancer reports encouraging results for women ...
More than two-thirds of deaths from ovarian cancer are attributable to high-grade serous carcinoma. In one particularly ...
Results demonstrate a significant survival benefit in the cTMB-H / HRP subset: median OS of almost 6 years (68 months) with Vigil vs. less than 2 ...
Ian C. Cook, MD, discusses the feasibility and benefits of adding bilateral salpingectomy to nongynecologic surgery.
A panelist discusses how National Comprehensive Cancer Network (NCCN) guidelines have influenced molecular testing in ovarian cancer, highlighting the importance of biomarkers like BRCA genes for ...
Suvemcitug combined with chemotherapy significantly improved PFS and OS in platinum-resistant recurrent ovarian cancer, nearly doubling median PFS and extending median OS. The trial demonstrated ...
In Ovarian Cancer, Interval Debulking Surgery Leads to Fewer Complications, Does Not Affect Survival
In this systematic review and meta-analysis, researchers examined outcomes among advanced ovarian cancer patients who ...
In the future, scientists could use drugs made from cannabis to fight ovarian cancer. A team of scientists testing the ...
The FDA-approved drug combination specifically targets low-grade serous ovarian cancer, which primarily affects younger women ...
A recent study links chemotherapy to impaired ovarian function and fertility through oxidative damage to ovarian follicles.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback